Bone Biologics Files Patent Application for Novel NELL-1 Protein Technology in Spine Fusion
核心洞察
Bone Biologics Corporation (搜索) has filed a patent application with the USPTO for its novel NELL-1 (搜索) protein technology targeting bone regeneration treatments.
The patent application covers compositions of rhNELL-1 (搜索) polypeptide and their therapeutic uses for treating various bone conditions.
If approved, the patent will strengthen the company's intellectual property portfolio and support advancement of its clinical development program for spine fusion applications.
Bone Biologics Corporation (搜索) (NASDAQ: BBLG, BBLGW) has filed a patent application with the United States Patent and Trademark Office (USPTO) for its novel NELL-1 (搜索) protein technology, marking a significant milestone in the company's development of orthobiologic products for spine fusion markets.
Patent Application Details
The patent application is specifically directed to compositions of rhNELL-1 (搜索) polypeptide and uses thereof for treating bone conditions. This filing represents a strategic move to protect the company's intellectual property as it advances its regenerative medicine platform focused on bone applications.
"This patent application marks a major milestone in our mission to bring effective treatments to spine fusion patients," said Jeffrey Frelick, Chief Executive Officer of Bone Biologics.
Strategic Impact on Development Program
If approved, the patent will strengthen Bone Biologics' intellectual property portfolio and support the company's strategic plan to advance its clinical development program. The company is currently focusing its development efforts on bone graft substitute products specifically designed for bone regeneration in spinal fusion procedures.
Technology Platform and Applications
Bone Biologics was founded to pursue regenerative medicine for bone applications, building on preclinical research of the NELL-1 (搜索) protein. The company is undertaking work with select strategic partners to advance this technology platform.
While the primary focus remains on spinal fusion procedures, Bone Biologics maintains additional rights to trauma and osteoporosis applications, potentially expanding the therapeutic reach of its NELL-1 (搜索) protein technology beyond spine fusion markets.
Company Background
The Burlington, Massachusetts-based company operates as a developer of orthobiologic products specifically targeting spine fusion markets. The company's approach centers on leveraging the regenerative properties of the NELL-1 (搜索) protein to address unmet medical needs in bone regeneration applications.